Compare Stocks: MDXG, PGEN, NAMS, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$31.12 -7.1%	$38.88	$22.10 ▼ $45.14	$2.63B	0.84	1.34 million shs	4.24 million shs
MDXG MiMedx Group	$4.77 -3.2%	$4.42	$3.03 ▼ $7.97	$718.60M	1.43	1.09 million shs	1.00 million shs
NAMS NewAmsterdam Pharma	$22.68 -2.7%	$26.60	$21.02 ▼ $42.21	$2.79B	0.09	1.61 million shs	2.27 million shs
PGEN Precigen	$7.44 -5.7%	$6.66	$2.99 ▼ $8.04	$2.81B	1.02	4.06 million shs	5.56 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-7.13%	-19.61%	-23.29%	-8.71%	+28.44%
MDXG MiMedx Group	-3.25%	+0.85%	+11.71%	+25.20%	-32.91%
NAMS NewAmsterdam Pharma	-2.74%	+7.08%	-15.53%	-28.52%	-14.96%
PGEN Precigen	-5.70%	+0.13%	+3.77%	+34.78%	+100.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$31.12 -7.1%	$38.88	$22.10 ▼ $45.14	$2.63B	0.84	1.34 million shs	4.24 million shs
MDXG MiMedx Group	$4.77 -3.2%	$4.42	$3.03 ▼ $7.97	$718.60M	1.43	1.09 million shs	1.00 million shs
NAMS NewAmsterdam Pharma	$22.68 -2.7%	$26.60	$21.02 ▼ $42.21	$2.79B	0.09	1.61 million shs	2.27 million shs
PGEN Precigen	$7.44 -5.7%	$6.66	$2.99 ▼ $8.04	$2.81B	1.02	4.06 million shs	5.56 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-7.13%	-19.61%	-23.29%	-8.71%	+28.44%
MDXG MiMedx Group	-3.25%	+0.85%	+11.71%	+25.20%	-32.91%
NAMS NewAmsterdam Pharma	-2.74%	+7.08%	-15.53%	-28.52%	-14.96%
PGEN Precigen	-5.70%	+0.13%	+3.77%	+34.78%	+100.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.86	Moderate Buy	$61.92	98.98% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	79.69% Upside
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.73	119.26% Upside
PGEN Precigen	2.80	Moderate Buy	$14.50	94.89% Upside

Current Analyst Ratings Breakdown

Latest MDXG, PGEN, NAMS, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CLDX Celldex Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$70.00 ➝ $88.00
9/23/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $57.00
9/22/2026	CLDX Celldex Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$68.00
9/22/2026	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $64.00
9/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$61.00 ➝ $72.00
9/15/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $50.00
9/8/2026	NAMS NewAmsterdam Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$52.00
8/27/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/27/2026	MDXG MiMedx Group	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $8.00
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$158K	15,467.43	N/A	N/A	$7.93 per share	3.92
MDXG MiMedx Group	$355.17M	1.96	$0.54 per share	8.90	$1.73 per share	2.76
NAMS NewAmsterdam Pharma	$22.50M	120.50	N/A	N/A	$5.97 per share	3.80
PGEN Precigen	$9.68M	274.01	N/A	N/A	$0.06 per share	124.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	119.28	28.06	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	8.65	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)

Latest MDXG, PGEN, NAMS, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	11.82	11.82
MDXG MiMedx Group	0.07	5.33	4.79
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
PGEN Precigen	2.15	4.58	3.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
MDXG MiMedx Group	79.15%
NAMS NewAmsterdam Pharma	89.89%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	5.20%
MDXG MiMedx Group	2.50%
NAMS NewAmsterdam Pharma	12.74%
PGEN Precigen	41.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
MDXG MiMedx Group	808	145.76 million	142.12 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
PGEN Precigen	47	356.51 million	208.92 million	Optionable

MDXG, PGEN, NAMS, and CLDX Headlines

Recent News About These Companies

Corient Private Wealth LP Sells 577,406 Shares of Precigen, Inc. $PGEN

4 hours ago | marketbeat.com

Precigen (NASDAQ:PGEN) Hits New 12-Month High - What's Next?

September 23 at 5:12 AM | americanbankingnews.com

Precigen (NASDAQ:PGEN) Hits New 1-Year High - Time to Buy?

September 23 at 4:39 AM | marketbeat.com

Precigen, Inc. (NASDAQ:PGEN) Receives Average Rating of "Moderate Buy" from Brokerages

September 23 at 4:28 AM | americanbankingnews.com

Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 23 at 4:28 AM | marketbeat.com

Precigen's AdenoVerse Receives FDA Platform Technology Designation

September 22 at 8:00 AM | finance.yahoo.com

Precigen receives FDA platform designation

September 21 at 9:52 AM | grafa.comG

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

September 21 at 7:00 AM | prnewswire.com

Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base

September 18, 2026 | finance.yahoo.com

Precigen (NASDAQ:PGEN) Sets New 12-Month High - What's Next?

September 17, 2026 | marketbeat.com

Precigen (NASDAQ:PGEN) Trading 6.8% Higher - Should You Buy?

September 16, 2026 | marketbeat.com

Stock Traders Buy Large Volume of Precigen Call Options (NASDAQ:PGEN)

September 16, 2026 | marketbeat.com

Precigen, Inc. $PGEN Shares Bought by Squarepoint Ops LLC

September 15, 2026 | marketbeat.com

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

September 14, 2026 | zacks.com

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

September 10, 2026 | zacks.com

Bank of New York Mellon Corp Makes New Investment in Precigen, Inc. $PGEN

September 8, 2026 | marketbeat.com

Corient Private Wealth LP Makes New Investment in Precigen, Inc. $PGEN

September 4, 2026 | marketbeat.com

Deutsche Bank AG Takes $1.14 Million Position in Precigen, Inc. $PGEN

August 31, 2026 | marketbeat.com

BlackRock Inc. Purchases New Position in Precigen, Inc. $PGEN

August 30, 2026 | marketbeat.com

Jeffrey Kindler Sells 185,000 Shares of Precigen (NASDAQ:PGEN) Stock

August 29, 2026 | insidertrades.com

Precigen, Inc. (NASDAQ:PGEN) Given Average Recommendation of "Moderate Buy" by Analysts

August 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, PGEN, NAMS, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$31.12 -2.39 (-7.13%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$30.98 -0.15 (-0.47%)

As of 07:41 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

MiMedx Group NASDAQ:MDXG

$4.77 -0.16 (-3.25%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.76 -0.01 (-0.31%)

As of 07:01 AM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

NewAmsterdam Pharma NASDAQ:NAMS

$22.68 -0.64 (-2.74%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$22.74 +0.06 (+0.28%)

As of 07:43 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Precigen NASDAQ:PGEN

$7.44 -0.45 (-5.70%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$7.46 +0.02 (+0.27%)

As of 07:41 AM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXG, PGEN, NAMS, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXG, PGEN, NAMS, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXG, PGEN, NAMS, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, PGEN, NAMS, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

MiMedx Group NASDAQ:MDXG

NewAmsterdam Pharma NASDAQ:NAMS

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXG, PGEN, NAMS, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXG, PGEN, NAMS, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXG, PGEN, NAMS, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, PGEN, NAMS, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

MiMedx Group NASDAQ:MDXG

NewAmsterdam Pharma NASDAQ:NAMS

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools